Opus Genetics (IRD) Amortization - Deferred Charges (2010 - 2017)
Opus Genetics (IRD) reported Amortization - Deferred Charges of $219577.0 for Q4 2017, down 34.07% on a QoQ basis from $333050.0 in Q2 2017.
Opus Genetics (IRD) has 6 years of Amortization - Deferred Charges data on file, last reported at $219577.0 in Q4 2017.
- Quarterly Amortization - Deferred Charges changed N/A year-over-year to $219577.0 in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $552627.0 (up 76.51% YoY) and the FY2017 annual result came in at $552627.0, up 76.51% from the prior year.
- Amortization - Deferred Charges retreated to $219577.0 in Q4 2017 per IRD's latest filing, from $333050.0 in the prior quarter.
- Across five years, Amortization - Deferred Charges topped out at $333050.0 in Q2 2017 and bottomed at $91653.0 in Q4 2013.
- The 4-year median for Amortization - Deferred Charges is $169887.0 (2016), against an average of $182300.1.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortization - Deferred Charges (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 219,577.00 |
| Dec 31, 2017 | 219,577.00 |
| Jun 30, 2017 | 333,050.00 |
| Jun 30, 2017 | 333,050.00 |
| Sep 30, 2016 | 143,203.00 |
| Sep 30, 2016 | 143,203.00 |
| Mar 31, 2016 | 169,887.00 |
| Mar 31, 2016 | 169,887.00 |
| Mar 31, 2014 | 206,172.00 |
| Mar 31, 2014 | 206,172.00 |
| Dec 31, 2013 | 91,653.00 |
| Dec 31, 2013 | 91,653.00 |
| Sep 30, 2013 | 112,559.00 |
| Sep 30, 2013 | 112,559.00 |
| Mar 31, 2011 | 97,667.00 |
| Mar 31, 2011 | 97,667.00 |
| Jun 30, 2010 | 180,080.00 |
| Jun 30, 2010 | 180,080.00 |